Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.01.20.524923Source: DataRank Database

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed Melanomas is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2023). On theSindex it has a DataRank of 0.269. It has been cited 5 times.

N/A

0.269DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)OA: greenTopics (23)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.269

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (18)

Min Xiao ORCID,Andrew V. Kossenkov ORCID,Tetiana Godok,Gregory Schuyler Brown ORCID,Dylan Fingerman ORCID

Live enrichment

PubMed:36711814 OpenAlex:https://openalex.org/W4317659325

National Institutes of Health

Grant: 2P01CA114046-11A1

Targeted Therapies in Melanoma

National Institutes of Health

Grant: 3P01CA025874-23S2

Expression pathways in melanoma progression for diagnosis and prognosis

National Institutes of Health

Grant: 5K01CA245124-06

Dissecting clonal diversity in melanoma to overcome therapy resistance andmetastasis

National Institutes of Health

Grant: 5R01CA047159-13

METASTASIS--BIOLOGICAL PHENOTYPE AND MODELS FOR THERAPY

National Institutes of Health

Grant: 5P30CA010815-28

CONSOLIDATED BASIC CANCER RESEARCH PROGRAM

National Institutes of Health

Grant: 1S10OD023586-01

Purchase of a Q Exactive HF mass spectrometer system for metabolomics

National Institutes of Health

Grant: 5R01CA182890-04

The role of genetic susceptibility in melanoma development

National Institutes of Health

Grant: 3U54CA224070-04S2

Rational approaches to melanoma therapy (PDXNet Administrative Supplement to R01CA241148)

greenLicense: cc-by-nc-nd

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2023/01/21/2023.01.20.524923.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2023.01.20.524923

repositoryhttps://doi.org/10.1101/2023.01.20.524923

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36711814

Fields of Study

Melanoma and MAPK PathwaysCAR-T cell therapy researchProtein Degradation and Inhibitors03 medical and health sciences0302 clinical medicine

Keywords

DasatinibMedicineNeuroblastoma RAS viral oncogene homologMEK inhibitorOncologyCombination therapyInternal medicineTrametinibTargeted therapyCancer researchCancerKRASMAPK/ERK pathwayKinaseImatinibBiologyColorectal cancerArticle

Sustainable Development Goals

SDG 0: No poverty